Keywords: EMEA, Tysabri, Elan, Biogen, GlaxoSmithKline, Arepanrix, Arzerra, Flu vaccines, Tamiflu
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
Article | 22 January 2010
The European Medicines Agency (EMEA) has finalized a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
